Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | BAY1436032: IDH1 inhibition in IDH1-mutated AML

Michael Heuser • 2 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia BAY1436032

Michael Heuser, MD, of Hannover Medical School, Hannover, Germany, reports the Phase I safety and efficacy results of the mutant IDH1 inhibitor, BAY1436032 in subjects with IDH1-mutated acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Michael Heuser

Final results of BRIGHT AML 1003
3:13
Final results of BRIGHT AML 1003
Michael Heuser • 12 Jun 2020
Is MRD monitoring prior to allograft standard in AML?
3:13
Is MRD monitoring prior to allograft standard in AML?
Michael Heuser • 25 Oct 2019
AML: mutant IDH1 inhibitor HMS-101
2:51
AML: mutant IDH1 inhibitor HMS-101
Michael Heuser • 25 Oct 2019
The clinical application of MRD testing in AML
1:30
The clinical application of MRD testing in AML
Michael Heuser • 1 Jun 2019

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Michael Heuser • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Michael Heuser • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Michael Heuser • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Michael Heuser • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals